Costa Barbosa Bessa Theolis, Santos de Aragão Erika, Medeiros Guimarães Jane Mary, de Araújo Almeida Bethânia
Gonçalo Moniz Institute, Oswaldo Cruz Foundation Unit in Bahia State, Rio de Janeiro, RJ, Brazil.
Institute of Collective Health, Federal University of Bahia, Salvador, BA, Brazil.
Biomed Res Int. 2017;2017:4765719. doi: 10.1155/2017/4765719. Epub 2017 Jan 4.
Based on an exploratory case study regarding the types of institutions funding the research and development to obtain new tuberculosis vaccines, this article intends to provoke discussion regarding the provision of new vaccines targeting neglected disease. Although our findings and discussion are mainly relevant to the case presented here, some aspects are more generally applicable, especially regarding the dynamics of development in vaccines to prevent neglected diseases. Taking into account the dynamics of innovation currently seen at work in the vaccine sector, a highly concentrated market dominated by few multinational pharmaceutical companies, we feel that global PDP models can play an important role throughout the vaccine development cycle. In addition, the authors call attention to issues surrounding the coordination of actors and resources in the research, development, manufacturing, and distribution processes of vaccine products arising from PDP involvement.
基于一项关于资助研发新型结核病疫苗的机构类型的探索性案例研究，本文旨在引发关于提供针对被忽视疾病的新型疫苗的讨论。尽管我们的研究结果和讨论主要与此处呈现的案例相关，但某些方面更具普遍适用性，特别是在预防被忽视疾病疫苗的研发动态方面。考虑到当前疫苗领域所呈现的创新动态，即由少数跨国制药公司主导的高度集中的市场，我们认为全球公私伙伴关系模式在整个疫苗研发周期中可发挥重要作用。此外，作者提请注意因公私伙伴关系的参与而在疫苗产品的研究、开发、生产和分销过程中出现的有关行为体和资源协调的问题。
